Q-omics provides the consensus-scored DPP4-DT profile across patient tissues and cancer cell-line models. DPP4-DT expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, DPP4-DT is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, DPP4-DT RNA expression shows 14,374 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, THCA, and TGCT as cancer lineages where DPP4-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPP4-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPP4-DT survival associations across molecular data types. DPP4-DT RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPP4-DT RNA expression–survival associations across cancer types. High DPP4-DT expression shows unfavorable associations in STAD, BLCA, LGG and DLBC, but favorable associations in LUAD and THCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for DPP4-DT RNA expression.
This table summarizes DPP4-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DPP4-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPP4-DT shows lower tumor expression in KICH, UCEC and BRCA and higher tumor expression in THCA, LUAD and KIRC. The THCA box plot shows higher DPP4-DT RNA expression in tumor versus normal tissue (log2 FC = +1.945, t-test p < 0.001).
This table shows molecular features associated with DPP4-DT in patient tissues and cancer cell lines. In patient samples, DPP4-DT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
